Drug intelligence / Profile preview

V-01

Development stage: Phase 3
Lead developer: Livzon Monoclonal Antibody
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

V-01 is a recombinant SARS-CoV-2 fusion protein vaccine developed by Livzon Pharmaceutical Group Inc. and Livzon Mabpharm Inc. It is designed for the prevention of SARS-CoV-2 infection (COVID-19). The vaccine is typically presented as a milky-white suspension for intramuscular injection, with a common strength of 10 μg (0.5 mL) per vial.

Brand names: Likang
Other names: V-01二价苗Recombinant SARS-CoV-2 Fusion Protein Vaccine

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on V-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-01.